United States — Food and Drug Administration & Replimune Group
8 shared events · Importance 3 · Last updated Sep 23, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
United States — Food and Drug Administration: The United States — Food and Drug Administration accepted the resubmission of the Biologics License Application for RP1, setting a target action date and scheduling an advisory committee meeting, which are crucial steps in the regulatory process for Replimune Group's drug.
Replimune Group: The FDA's acceptance of the BLA resubmission for RP1 is a significant step towards potential accelerated approval, which could lead to increased revenue and market presence for Replimune Group. However, the stock price was down in pre-market trading, indicating some investor caution.
Jun 26, 2026 · 8 articles
Regulatory
United States — Food and Drug Administration: Published the Complete Response Letter rejecting Replimune's BLA and earlier briefing documents questioning the IGNYTE study data, triggering the share decline that underpins the lawsuits.
Replimune Group: Central defendant in the securities class actions and issuer of the rejected BLA; its shares reportedly collapsed from $4.76 to $1.70 in April 2026 and it faces ongoing litigation and regulatory setbacks.
Jul 29, 2026 · 139 articles
Regulatory
United States — Food and Drug Administration: The United States — Food and Drug Administration issued the Complete Response Letter rejecting Replimune Group's BLA for RP1 with Nivolumab, citing inadequate trial evidence. Its regulatory stance reinforces strict evidentiary standards for accelerated approval.
Replimune Group: Replimune Group is the target of the securities class action and the company whose BLA was rejected by the United States — Food and Drug Administration, triggering a roughly 84 percent two-day share price collapse. The litigation and regulatory setback severely damage its near-term prospects and investor confidence.
Sep 03, 2026 · 6 articles
Regulatory
United States — Food and Drug Administration: The FDA is the subject of the restructuring, which could reshape its leadership and regulatory approach, affecting drug approvals and AI oversight.
Replimune Group: Replimune Group received accelerated approval for its melanoma drug after a regulatory battle, benefiting from FDA decisions.
Aug 25, 2026 · 6 articles
Domestic
United States — Food and Drug Administration: The FDA is the agency being led. It faces staff losses, morale issues, and policy controversies; Overton's nomination could exacerbate these challenges.
Replimune Group: Replimune Group, a biotech, had disagreements with the FDA under Makary. Overton's nomination may affect rare-disease drug approvals.
Aug 19, 2026 · 101 articles
Tech
United States — Food and Drug Administration: The FDA is the regulatory authority that must approve the vaccine. Approval could come as soon as 2027, but the agency's review process and potential political interference from the administration could affect the timeline.
Replimune Group: Replimune recently received FDA approval for its melanoma therapy Tudriqev. The success of the Moderna-Merck vaccine may increase competition but also validates the broader field of cancer immunotherapy.
Aug 19, 2026 · 126 articles
Regulatory
United States — Food and Drug Administration: The FDA granted approval for mFLUSIVA, marking a regulatory milestone and demonstrating its role in vaccine oversight despite internal controversies.
Replimune Group: Replimune Group was mentioned in context of FDA scrutiny under Makary, but is not directly affected by this approval.
Aug 05, 2026 · 105 articles
Domestic
Replimune Group: Replimune Group>>> experienced rejection of its melanoma therapy by the United States — Food and Drug Administration>>> under Marty Makary>>>'s leadership, leading to public criticism and contributing to the pressure for his ouster.
May 08, 2026 · 114 articles
95
United States — Food and Drug Administration rejected BLA Replimune GroupReplimune Securities Fraud...
95
United States — Food and Drug Administration rejected biologics license application Replimune GroupReplimune Securities Fraud...
95
United States — Food and Drug Administration rejected biologics license application Replimune GroupReplimune Securities Class...
85
United States — Food and Drug Administration published briefing documents Replimune GroupReplimune Securities Fraud...
80
Replimune Group submitted unplanned analysis data United States — Food and Drug AdministrationReplimune Securities Fraud...
75
Replimune Group failed to address study concerns United States — Food and Drug AdministrationReplimune Securities Fraud...
70
Replimune Group submitted unplanned analysis United States — Food and Drug AdministrationReplimune Securities Fraud...
60
United States — Food and Drug Administration flagged response criteria Replimune GroupReplimune Securities Fraud...
60
United States — Food and Drug Administration published briefing documents Replimune GroupReplimune Securities Fraud...
50
United States — Food and Drug Administration recommended Phase 3 data Replimune GroupReplimune Securities Fraud...
50
United States — Food and Drug Administration recommended Phase 3 data Replimune GroupReplimune Securities Fraud...
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States — Food and Drug Administration and Replimune Group interact across events, view sentiment trends, and discover connected entities.
Open Dashboard